



"Non-alcoholic fatty liver disease (NAFLD) association with cardiovascular disease: A cohort study"

Dr Fahimeh Safarnezhad

PhD. Medical Genetics, Gastrointestinal and Liver Diseases Research Center,
Iran University of Medical Sciences

Dr Farhad Zamani, Corresponding Author

Introduction:

- ▶ NAFLD is a leading cause of **chronic liver disease** worldwide
- ▶ Defined as the **presence of hepatic steatosis** after excluding other causes of hepatic fat accumulation such as
 - ▶ Excessive alcohol consumption
 - ▶ Viruses
 - ▶ Drug-related hepatitis
- ▶ The global prevalence of NAFLD, **25.2%** in a meta-analysis of 86 studies by Younossi et al
- ▶ The increase in the prevalence of NAFLD has usually followed the **obesity** pandemic in children and adults globally although a considerable fraction of subjects are **lean**

Introduction:

- ▶ A number of hepatic complications from **simple steato-hepatitis to cirrhosis and hepatocellular carcinoma** can be attributed to NAFLD
- ▶ NAFLD is considered to be a hepatic manifestation of **metabolic syndrome**
- ▶ NAFLD may be associated with metabolic co-morbidities such as **diabetes mellitus (DM)** and **dyslipidemia**
- ▶ The **non-liver related deaths** remain far more common than liver-related deaths
- ▶ **Our study Aim**
 - ▶ To determine an independent association between NAFLD and CVD events₃

MATERIALS AND METHODS

- ▶ **Study setting and sampling frame**
 - ▶ Phase 1 started in 2009-2010
 - ▶ Phase 2 started in 2016-2017
- ▶ Data obtained using primary health records in urban and rural areas
- ▶ 16 strata according **gender** and the following **age group** ranges within 10-90 years: 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79 and 80-89
- ▶ Members were contacted annually to provide the outcomes related to **fatal** and **non-fatal CVD**

Figure 1 Flow diagram of phase I and phase II included and excluded participants



MATERIALS AND METHODS

► Outcomes Evaluation

- Atherosclerosis CVD (**ASCVD**) and the number of occurrences was considered as **outcomes**
- Hospital **discharge** records and **death** certificates for fatal CVD events were recorded
- Confirmation of associated outcomes was undertaken by an internist in the cohort study group

MATERIALS AND METHODS

- ▶ The diagnosis of NAFLD was by performed by **sonography** by one expert sonographer in phase 1 of the cohort in our research center
- ▶ NAFLD was defined as hepatic steatosis in participants with no history of excess consumption of alcohol, drug-related steatosis or viral or hereditary steatogenic hepatitis
- ▶ Anthropometric measures (**height, weight**) and **blood pressure** were measured by trained healthcare staff
- ▶ Whole blood samples (10 mL) were taken
 - ▶ Fasting blood sugar (**FBS**), high-density lipoprotein cholesterol (**HDL**), low-density lipoprotein cholesterol (**LDL**), triglycerides (**TG**)

RESULTS

- ▶ All cases were 4808:
 - ▶ 2667 were male and 2141 female
- ▶ NAFLD prevalence
 - ▶ **40.67%** (95%CI: 38.89%-42.45%) for **males** and **43.58%** (95%CI: 41.52%-45.65%) for **females** (P = 0.0359)
- ▶ The results indicate that **all characteristics except HDL** were **significantly higher** in participants **with NAFLD** than those without NAFLD
- ▶ DM prevalence
 - ▶ For **males**:
 - ▶ **14.79%** (95%CI: 12.77%-16.81%) **with NAFLD** and **5.07%** (95%CI: 4.04%-6.10%) **without NAFLD** (P < 0.001)
 - ▶ For **females**
 - ▶ **27.27%** (95%CI: 24.47%-30.08%) **with NAFLD** and **8.06%** (95%CI: 6.55%-9.57%) **without NAFLD** (P < 0.001)


Table 1 Basic characteristics of population study in people without and with non-alcoholic fatty liver disease

Characteristics	mean \pm SD		P value
	Without NAFLD	With NAFLD	
Men (n = 2667)	n = 1149	n = 1518	
Age (yr)	42.02 \pm 17.80	48.35 \pm 14.24	< 0.001
BMI (kg/m ²)	24.35 \pm 3.65	29.71 \pm 3.96	< 0.001
WC (cm)	84.82 \pm 10.39	99.57 \pm 9.65	< 0.001
DBP (mmHg)	73.76 \pm 12.18	80.72 \pm 12.07	< 0.001
SBP (mmHg)	114.13 \pm 14.65	121.81 \pm 15.71	< 0.001
FBS (mg/dL)	94.48 \pm 26.74	104.45 \pm 33.03	< 0.001
HOMA-IR	1.75 \pm 1.42	2.90 \pm 2.33	< 0.001
TG (mg/dL)	123.35 \pm 76.91	173.63 \pm 101.92	< 0.001
HDL (mg/dL)	45.65 \pm 11.51	40.31 \pm 10.94	< 0.001
LDL (mg/dL)	99.99 \pm 30.30	112.27 \pm 30.42	< 0.001
Women (n = 2141)	n = 934	n = 1207	
Age (yr)	37.88 \pm 15.09	50.20 \pm 12.37	< 0.001
BMI (kg/m ²)	27.01 \pm 4.83	33.11 \pm 4.76	< 0.001
WC (cm)	84.72 \pm 11.34	100.25 \pm 10.48	< 0.001
DBP (mmHg)	72.32 \pm 12.39	80.21 \pm 12.88	< 0.001
SBP (mmHg)	110.34 \pm 15.77	121.65 \pm 18.03	< 0.001
FBS (mg/dL)	94.97 \pm 30.36	115.22 \pm 49.96	< 0.001
HOMA-IR	2.20 \pm 1.62	3.43 \pm 3.13	< 0.001
TG (mg/dL)	115.25 \pm 67.10	173.92 \pm 118.78	< 0.001
HDL (mg/dL)	48.92 \pm 11.81	42.98 \pm 11.68	< 0.001
LDL (mg/dL)	104.15 \pm 30.62	116.51 \pm 31.06	< 0.001

RESULTS

- ▶ In **males**, the incidence of **non-fatal CVD** events was **significantly higher** in individuals **with NAFLD** than those without NAFLD
- ▶ The incidence of **fatal and non-fatal CVD** events were **higher** in **females with NAFLD** than those without NAFLD; however, these differences were not statistically significant

W: Women
 W: without NAFLD
 M: Male
 N: NAFLD case



RESULTS

- ▶ A **positive simple association** was detected between **NAFLD** and **non-fatal CVD** events in **males** (Hazard ratios = 1.606; 95%CI: 1.166-2.212; $P = 0.004$)
- ▶ **No independent association** was detected between them in the multiple Cox regression models
- ▶ **No association** between **NAFLD** and **CVD** events in **females** on the simple and multiple Cox proportional hazard models
- ▶ **Age** and **diabetes mellitus** have an **association** with **fatal** and **non-fatal CVD** events
- ▶ There were not any **independent association** between **diabetes mellitus** and **fatal CVD** events in **women**

Table 2 The results of Cox proportional hazard models on fatal and non- fatal cardiovascular events as outcome, and Non-alcoholic fatty liver disease, diabetes mellitus and age as potential predictors

Sex	Outcomes	Simple Cox proportional model			Multiple Cox proportional model		
		Wald	HR (95% CI)	P value	Wald	HR (95% CI)	P value
NAFLD							
In men	Fatal CVD events	0.963	1.345 (0.744-2.430)	0.326	0.104	0.903 (0.486-1.677)	0.747
	Non-fatal CVD events	8.400	1.606 (1.166-2.212)	0.004	3.723	1.384 (0.995-1.925)	0.054
In women	Fatal CVD events	1.570	1.694 (0.743-3.863)	0.210	0.002	1.178 (0.491-2.829)	0.714
	Non-fatal CVD events	2.327	1.416 (0.906-2.214)	0.127	0.063	0.941 (0.584-1.516)	0.802
Diabetes mellitus							
In men	Fatal CVD events	37.13	6.692 (3.631-12.334)	< 0.001	8.398	2.688 (1.377-5.247)	0.004
	Non-fatal CVD events	30.98	2.999 (2.037-4.415)	< 0.001	8.789	1.835 (1.240-2.667)	< 0.001
In women	Fatal CVD events	10.99	4.034 (1.769-9.201)	< 0.001	2.165	1.867 (0.813-4.290)	0.141
	Non-fatal CVD events	40.71	4.358 (2.773-6.850)	< 0.001	14.35	2.507 (1.558-4.032)	< 0.001
Age							
In men	Fatal CVD events	75.35	1.122 (1.094-1.152)	< 0.001	62.82	1.114 (1.085-1.144)	< 0.001
	Non-fatal CVD events	69.12	1.043 (1.033-1.054)	< 0.001	56.86	1.041 (1.030-1.052)	< 0.001
In women	Fatal CVD events	47.49	1.134 (1.094-1.176)	< 0.001	44.91	1.133 (1.093-1.176)	< 0.001
	Non-fatal CVD events	63.59	1.068 (1.051-1.085)	< 0.001	48.60	1.062 (1.044-1.081)	< 0.001

DISCUSSION

- ▶ Stepanova et al
 - ▶ An **independent association between NAFLD and CVD** events in the US population after a 14.3-year follow-up, although they found no association between CVD-related death and NAFLD
- ▶ Chan et al
 - ▶ **No association between NAFLD and prevalent Ischaemic Heart Disease (IHD)** events among patients with DM
- ▶ Hamaguchi et al
 - ▶ **NAFLD as an independent predictor for CVD** events
- ▶ Zeb et al
 - ▶ NAFLD can be considered a **risk factor for non-fatal cardiac heart disease** independent of traditional cardiovascular risk factors
- ▶ Kim et al
 - ▶ Found **no association between CVD death and NAFLD**

DISCUSSION

- ▶ Targher et al
 - ▶ Screening and **surveillance strategies** for cardiovascular diseases in patients with NAFLD, particularly those with steatosis
 - ▶ **People with NAFLD will die of CVD** before they die from an advanced liver disease
- ▶ Alexander et al
 - ▶ Meta-analysis of matched cohort study of 18 million European adults
 - ▶ **Did not report any association between acute myocardial infarction or stroke and NAFLD**, when the related analyses were adjusted based on the established cardiovascular risk factors
- ▶ Motamed et al
 - ▶ Found an **association between NAFLD and 10-year CVD** risk
- ▶ Han et al
 - ▶ A **significant association between NAFLD and CVD** risk

DISCUSSION

- ▶ There are common risk factors, such as
 - ▶ Obesity
 - ▶ Diabetes mellitus
 - ▶ Insulin resistance

- ▶ Our results emphasize that **age** and **DM** can be considered **major mediators** in the development of **non-fatal CVD** events in **males with NAFLD**
- ▶ A **high prevalence of DM in individuals with NAFLD** and a strong **association** between **CVD and DM** can increase the incidence of CVD events in patients with NAFLD
- ▶ The association between **age** with both **NAFLD and CVD** events are another cause of the increased incidence of CVD events in patients with NAFLD

DISCUSSION

- ▶ We evaluated the association between **NAFLD and CVD** events in a prospective study with a **7-year follow-up** period
- ▶ **Fatal CVD** events
 - ▶ **Increased** slightly in individuals (males and females) **with NAFLD** compared to those without NAFLD, but this increase was not statistically significant
- ▶ **Non-fatal CVD** events
 - ▶ **Males with NAFLD** developed a **significant slightly higher** number of **CVD** events in the 7-year follow-up compared to males without NAFLD, this was not significant in females
- ▶ By considering **DM** and **age** as potential mediators between NAFLD and CVD events,
 - ▶ **No independent relationship** was detected between **NAFLD** at the beginning of the study and **fatal and non-fatal CVD** events in the 7-year follow-up in either males or females

DISCUSSION

- ▶ Our study showed that there is no independent association between NAFLD and CVD events
- ▶ The potential mediators of **age** and a history of **DM** were **confounding variables** for the association of NAFLD and the occurrence of new cases of CVD
- ▶ Our Study Limitations:
 - ▶ Duration of the follow-up: The **84-month follow-up** for participants without a history of a CVD event **may not be adequate** to monitor and establish full associations of CVD events between individuals with and without NAFLD
 - ▶ NAFLD in this study was evaluated using **sonography** rather than **liver biopsy**, which is regarded as the ‘golden standard’
 - ▶ Some patients with **silent CVD events** in data collection strategy would not have been included in the study

DISCUSSION

► In conclusion

- Although we found a **significant association between NAFLD and non-fatal CVD** events in **males**, **no independent association** was detected between NAFLD and fatal and non-fatal CVD events in either males or females
- **Diabetes mellitus** and **age** can be considered the principle mediators in CVD

Thank You For Your Kind Attention